Weiden P L, Thomas E D, Storb R, Fefer A, Neiman P E, Clift R A, Buckner C D, Lerner K G
Compr Ther. 1976 Apr;2(4):57-62.
Human marrow transplantation has resulted in observations of fundamental significance in understanding both aplastic anemia and acute leukemia. For example, the observation that transplanted marrow can grow successfully in patients with aplastic anemia indicates that the disease is due to a defect in the marrow precursor cells and not in the marrow microenvironment. Similarly, the observation of recurrent leukemia in donor cells has important implications. Nonetheless, marrow transplantation is sufficiently established therapeutically to be considered the treatment of choice for patients with severe aplastic anemia, and a realistic alternative for patients with recurrent acute leukemia. We suggest that patients be managed with regard to marrow transplantation according to the general approach outlined in Table 3. Marrow transplantation and histocompatibility typing are available at increasing numbers of institutions throughout the world. More and more patients with either severe aplastic anemia or recurrent acute leukemia should have marrow transplantation available to them when it is indicated as part of optimal management of these no longer hopeless diseases.
人类骨髓移植在理解再生障碍性贫血和急性白血病方面带来了具有根本重要性的观察结果。例如,移植的骨髓能够在再生障碍性贫血患者体内成功生长这一观察结果表明,该疾病是由于骨髓前体细胞存在缺陷,而非骨髓微环境存在缺陷。同样,供体细胞中出现复发性白血病这一观察结果也具有重要意义。尽管如此,骨髓移植在治疗上已足够成熟,可被视为重症再生障碍性贫血患者的首选治疗方法,以及复发性急性白血病患者切实可行的替代治疗方法。我们建议,应根据表3中概述的一般方法对患者进行骨髓移植管理。骨髓移植和组织相容性分型在世界上越来越多的机构都可进行。越来越多的重症再生障碍性贫血或复发性急性白血病患者,在这些不再是毫无希望的疾病的最佳管理中,当有指征时应能获得骨髓移植治疗。